BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Menarini Group Partners with Insilico Medicine on AI-Discovered Oncology Asset in $550M Licensing Deal

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, si...

January 13, 2025 | News

Biocytogen and Acepodia Join Forces to Advance Precision Oncology with Dual-Payload Bispecific ADCs

Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen’s RenLite® meets Acepodia’s...

January 08, 2025 | News

Dizal’s China-Origin Sunvozertinib Secures FDA Priority Review for EGFR Exon20ins NSCLC

If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with E...

January 08, 2025 | News

GORTEC's Phase 3 Trial Shows Nivolumab Improves Disease-Free Survival in High-Risk Head and Neck Cancer Patients

GORTEC, known as Head and Neck Radiation Oncology Group, announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, ...

January 08, 2025 | News

I-Mab Prioritizes Lead Program Givastomig to Advance Precision Immuno-Oncology for Gastric Cancer

Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization ...

January 07, 2025 | News

Astellas Pharma Announces NMPA Approval of Zolbetuximab in China for Advanced Gastric and GEJ Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the National Medical Products Administration (N...

January 06, 2025 | News

European Commission Approves Amivantamab Plus Lazertinib for First-Line Treatment of EGFR-Mutated NSCLC

Janssen-Cilag International NV, a Johnson & Johnson company,announced the European Commission (EC) approval for a Type II variation indication extensio...

January 03, 2025 | News

HKSH Cancer Centre Hosts Sixth Symposium on Cancer Management, Celebrates One Year of Proton Therapy Milestones

HKSH Cancer Centre organised the sixth "HKSH Symposium on Advances in Cancer Management" ("The Symposium") which was held on 12 December 2024 at ...

January 03, 2025 | News

Verastem Oncology’s NDA for Avutometinib-Defactinib Combo in KRAS Mutant LGSOC Accepted by FDA with Priority Review

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced that the U.S. Food a...

January 02, 2025 | News

Innovent Biologics and Roche Forge Strategic Alliance to Advance DLL3-Targeted ADC for Small Cell Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

January 02, 2025 | News

Alphamab Oncology Receives NMPA Approval for Phase I/II Trial of Groundbreaking Subcutaneous Co-Formulation JSKN033

Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co...

December 27, 2024 | News

Achilles Therapeutics Transfers TRACERx and MAP Data to AstraZeneca in $12M Deal

Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transa...

December 25, 2024 | News

Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in NSCLC

Daiichi Sankyo and AstraZeneca have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DX...

December 25, 2024 | News

Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025

Antibody-Drug Conjugates (ADCs) represent a paradigm shift in oncology, offering targeted cancer treatment that minimizes collateral damage to healthy cell...

December 23, 2024 | News

Stay Connected